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during 2008. Appeals were evaluated according to literature sent and justiﬁcations. 
The budgetary impact was measured. RESULTS: A total of 960 chemotherapy bills 
from this HP were evaluated totaling US$1,277,181.12. There was at least one point 
of recommended coverage denial in 471 (49%) either of materials, drugs or the entire 
procedure, representing US$157,965.77. Denial was based on the best available evi-
dence for each treatment. There were 100 appeals (US$47,889.11) following those 
denials, but 75% or US$35,939.53 was not reversed. We observed that contestations 
were more frequent for high cost drugs like Trastuzumab, Gemzar or Rituximab. The 
most frequent complaint was patient weight variation leading to the use of extra vials 
of these drugs, not previously approved. Interestingly, no such request was made for 
low-cost drugs. However, none of these variations resulted in dose increase larger than 
5%, not justifying the waste of nearly all the drug in the vial. In none of these appeals 
was any literature sent. The appeals reversed were basically bureaucratic cases in 
which the coverage was denied based of incorrect form ﬁllings or lack of any 
documentation. CONCLUSIONS: One in four denial appeals was reversed due to 
bureaucratic paper work. None of the other appeals was accompanied by sup- 
portive literature. Appeals are more frequent when high cost drugs are used in the 
chemotherapy.
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OBJECTIVES: To estimate annual expected economic burden (EEB) of treating 
advanced soft tissue sarcomas (STS) with trabectedin in Russia. METHODS: EEB 
of treating advanced STS with trabectedin was calculated in a model in comparison 
with EEB of bevacizumab for metastatic colorectal cancer (CRC) and sorafenib 
for advanced renal cancer (RC). All studied drugs are used for advanced cancer and 
have similar efﬁcacy of expected increase of survival for several months. The model 
was based on the following assumptions: 1) trabectedin is given to patients with a 
new case of STS revealed at advanced stage and resistant to ﬁrst-line therapy; 2) 
according to federal standards of care, bevacizumab is given to 80% of patients with 
a new case of metastatic CRC; and 3) sorafenib is given to all patients with a new 
case of metastatic RC. Number of new cases of advanced cancer was taken from the 
annual report about cancer morbidity and mortality in Russia. Dosing regimens of 
drugs were taken from clinical studies. Prices of bevacizumab and sorafenib were taken 
from RMBC database, price of trabectedin was proposed by the manufacturer. 
RESULTS: EEB of trabectedin was estimated to be 2.3 billion rubles (a. US$76.4 
million) per year, EEB of bevacizumab for metastatic CRC was 16.0–21.3 billion 
rubles (a. 533.1–US$710.8 million), EEB of sorafenib for metastatic RC was 5.8 
billion rubles (US$194.5 million) per year. CONCLUSIONS: EEB of trabectedin is 
less than of some other drugs for advanced cancer with comparable efﬁcacy that have 
already been recommended for use in a health care system. Bevacizumab is included 
into federal standards of care, sorafenib is included into Essential Drug List, that 
means that these drugs should be available to patients. Therefore trabectedin looks 
affordable for the system.
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OBJECTIVES: To calculate the NNT to avoid a recurrence of GIST after resection, 
to compare the cost of adjuvant treatment with imatinib (IM) with the cost of 
recurrence, and to estimate a budget impact from the Brazilian Public Health 
Care System (SUS) perspective. METHODS: Available relative risk reduction at 1 
year from the Z9001 clinical trial and historical rate of recurrence for no adjuvant 
treatment were applied to estimate absolute risk reduction and NNT. Adjuvant 
treatment effect was extrapolated to 3-year period as ongoing trials are investigating 
longer treatment duration (SSG XVIII). A 5-year time horizon was set for cost 
comparison and Budget Impact Analysis (BIA). Incremental Cost to Avoid 
Recurrence (ICAR) was deﬁned as the difference between the cost of adjuvant 
treatment (IM, monitoring) and the cost of recurrence (IM, surgery, monitoring, 
best supportive care). ICAR was applied to adjuvant GIST incidence for BIA. Epide-
miological data (incidence, proportion of resectables); health access, diagnosis 
and expected adjuvant treatment rates were obtained from literature. Resource utiliza-
tion and cost data came from ofﬁcial guideline and administrative databases, literature 
and expert opinion. Costs are reported in 2007 Euros. A 5% discount rate was 
applied. Univariate sensitivity analysis was performed. RESULTS: The NNT to 
avoid a recurrence was estimated at 2.1 based on extrapolated GIST recurrence 
risk proﬁle in Brazil. Cost of adjuvant treatment was a50,298 and the cost of a recur-
rence a61,998. Annual ICAR was a8,725. The annual impact on the Ministry of 
Health budget was 0.01%, which included impact on infrastructure (e.g. monitoring 
costs) of SUS. Results were sensitive to the recurrence rate and adjuvant treatment 
duration. CONCLUSIONS: Considering that imatinib is already reimbursed by 
SUS for metastatic/unresectable GIST, adjuvant therapy for primary GIST represents 
good value for money for the prevention of recurrence, and an annual budget impact 
of 0.01%.
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OBJECTIVES: The purpose of the study was to evaluate the cost effectiveness and 
budget impact of temsirolimus compared to interferon alpha-2A (IFN) in any given 
population of metastatic renal cell carcinoma (mRCC). METHODS: Economic evalu-
ations were performed from a US managed care perspective over a 30 months period. 
Cost of treatment was the summation of drug’s cost, administration cost, premedica-
tion cost, and cost of associated adverse events. Outcomes measure for economic 
evaluations was progression free life months gained. Cost effectiveness was conducted 
using a Markov state-transition model in TreeAge®. Time dependent transition prob-
abilities were calculated using multistate Kaplan Meier estimators based on clinical 
trial data. An Excel-based budget impact model was developed to compare two sce-
narios, one for the interferon scenario and one for the temsirolimus scenario. Inputs 
were obtained from SEER registry, clinical trial, and US census bureau. Sensitivity 
analyses were performed. RESULTS: The model yielded ICER $8944 per progression 
free life month gained. For a hypothetical managed care plan with 500,000 members, 
the Budget Impact model estimated 33 patients with mRCC. A 75% (n  25) of mRCC 
was eligible to receive ﬁrst line therapy. A 95% (n  24) eligible patients would be 
treated with IFN. Assuming that temsirolimus was available to 12% of eligible patients 
the expected 30 months cost would be US $18215.7 per patient compared 
with $15,557.90 had all patients been treated with IFN alone. CONCLUSIONS: 
Temsirolimus was found not to be dominantly cost effective compare to interferon 
alpha-2A. This ﬁnding is indicative of two challenges: 1) temsirolimus needs to be 
available at a reduced cost; 2) its threshold for cost-effectiveness needs to be adjusted 
according to relative clinical efﬁcacy. The budgetary impact of adding temsirolimus 
to health plan was estimated to be minimal. While its current availability allows new 
treatment options, temsirolimus may be too expensive to use in some managed care 
plans.
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OBJECTIVES: To perform a cost analysis comparing the management of adverse 
events (AEs) and their associated cost in current clinical practice of bevacizumab (BEV) 
 interferon alpha-2a (IFN) versus sunitinib (SUN) in patients with metastatic renal 
cell carcinoma (mRCC) in Spain. METHODS: A decision analytic model was devel-
oped to compare the costs derived from the management of 40 grade 3/4 AEs in 
patients with mRCC, using published data from published trials (BEV      IFN: Escudier 
B. Lancet 2007;370:2103–11. SUN: Motzer RJ. N Engl J Med 2007;356:115–24). 
The analysis was performed from the Spanish public hospitals perspective. Estimation 
of resources used in managing AEs was made through an Expert Panel. Cost evalua-
tion (a, 2009 values) included direct medical costs: outpatient visits, diagnostic and    
laboratory tests, hospitalization stays, surgeries, and medication. Unitary cost data 
were collected from Spanish Data Base of Sanitary Costs 2009 and Catalogue of            
Medicinal Products. RESULTS: Average cost of managing the grade 3/4 AEs per 
patient was a568 for BEVIFN and a940 for SUN. The per patient cost savings of 
a372 when using BEVIFN corresponds to a relative saving of 40% when compared 
to SUN. The main drivers for SUN costs were related to the management of laboratory 
abnormalities, anaemia, mucosal inﬂammation, decline in ejection fraction, diarrhea, 
thrombocytopenia, rash, epistaxis, and vomiting. In comparison, the main costs for 
BEVIFN were associated to the management of gastrointestinal perforation, bleeding, 
proteinuria, venous thromboembolic event, anorexia and anaemia. CONCLUSIONS: 
The costs of managing side effects of SUN treatment are signiﬁcantly greater than 
those for BEVIFN in Spain. When selecting treatment options, the management costs 
of these side effects may be an important factor to consider for health care payers.
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OBJECTIVES: New treatment options for advanced NSCLC can offer improved sur-
vival over standard chemotherapy and should also offer value for money. Bevaci-
zumab, a humanised monoclonal antibody (MAb) against VEGF, plus chemotherapy 
increases progression-free survival (PFS; median 6.8 months) in advanced NSCLC 
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patients versus chemotherapy alone. Cetuximab, a MAb targeting EGFR, has also 
shown some improvements in these patients (median PFS 4.8 months) when combined 
with cisplatin plus vinorelbine (FLEX study). The aim of this study was to compare 
the costs of treating NSCLC with BCG or CVC in Germany. METHODS: A Markov 
model was used to compare drug and administration costs associated with treating 
advanced or recurrent NSCLC with BCG or CVC. The model assumes patients move 
from non-progressive to progressed disease prior to death, according to transition 
probabilities derived from an indirect comparison (IC) of BCG and CVC efﬁcacy in 
terms of PFS using respective pivotal trial data and appropriate IC methodology. Cost 
data were derived from local sources. Drug costs assumed chemotherapy was given 
for up to 6 cycles, cetuximab was administered initially at 400 mg/m2 (then 250 mg/m2 
weekly) until progression and bevacizumab 7.5 mg/kg was administered until progres-
sion. Sensitivity analyses were run with different patient characteristics. RESULTS: 
The mean total cost of BCG treatment was a4,713 less per patient than CVC (a28,342 
versus a33,055, respectively). Adding bevacizumab to chemotherapy was less costly 
than CVC (a18,796 versus a29,502, respectively) and the administration cost for BCG 
was also less costly than for CVC (a391 versus a1,179, respectively). CONCLU-
SIONS: Bevacizumab targeted-therapy is less costly than cetuximab in Germany, thus 
from a budget perspective, offers the best value for money strategy for improving 
outcomes in patients with advanced non-squamous NSCLC. Furthermore, costs 
savings with BCG in Germany will be increased since gemcitabine has recently come 
off-patent.
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OBJECTIVES: To evaluate direct costs of pulmonary lobectomy hospitalization com-
paring two different surgical techniques: stapler (ST) versus electrocautery and hae-
mostatic sealant patch (ES) to Italian Hospitals. METHODS: The cost comparison 
analysis was based on the clinical pathway drawn up from the information provided 
by the medical team of the hospital enrolled. Resource use data including staff time, 
diagnostic tests, drugs and consumables came from a randomized controlled trial 
including 40 patients (20 in each group). Technology equipment utilization and 
maintenance, operating room costs, administrative and general costs, and 30 days post 
surgery hospital resource consumption were also considered. Overheads were allo-
cated on the basis of hospitalization rate and procedures weight. Unit costs were col-
lected either from hospital accounting or regional tariffs for specialist services, when 
hospital data are not available. The analysis was conducted from hospital perspective. 
RESULTS: On average, a patient submitted to a pulmonary lobectomy costs around 
a10,000. This amount could vary from a9,200 (using ES) to a10,800 (using ST). Cost 
savings in the ES group were driven by the lower incidence of complications. In fact 
the lower overall incidence (50% vs. 95%, P  0.0001) and duration of air leakage 
(1.7 days vs. 4.5 days, P  .0001) in the ES group impacts signiﬁcantly on the mean 
time to hospital discharge (11 days vs. 14.3 days) and consequently on costs. Exclud-
ing general costs the main key cost driver is staff time (42%), secondly the consum-
ables (34%) and then operating room costs (12%). CONCLUSIONS: There is an 
overall saving of around a1600 using electrocautery dissection and the haemostatic 
sealant patch for a pulmonary lobectomy. We found that among patients submitted 
to this surgery procedure, ES can signiﬁcantly reduce air leakage incidence and dura-
tion and decrease hospitalization rates. However further multi-centre research should 
be developed considering different clinical and organizational settings.
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OBJECTIVES: Novel combination therapies for advanced NSCLC can offer improved 
survival over chemotherapy alone. Besides effectiveness new therapies must also dem-
onstrate acceptable tolerability. Furthermore, toxicities can result in potentially high 
additional treatment costs. This analysis thus explores the treatment costs of adverse 
events (AEs) related to two newly available ﬁrst-line NSCLC therapies consisting 
of either Bevacizumab (BEV) combined with chemotherapy (CT) or Cetuximab (C) 
combined with cisplatin  vinorelbine (CV). METHODS: All published AEs and their 
incidences as reported in the AVAiL trial (7.5 mg/kg, Reck et al. 2009) or the E4599         
trial (15 mg/kg, Sandler et al. 2006) were taken into consideration for the BEV            CT 
analyses, whereas AE data for the CCV regimen was retrieved from the FLEX trial 
(Pirker et al. 2009). A systematic literature search was performed to collect published 
information on standard treatment patterns and costs of AEs. Two oncologists in 
France were additionally interviewed to substantiate and complement the data on 
medical resource utilization for the AEs under study. These resource use items were 
then assigned unit costs (charges) based on tariffs for France. A model was subse-
quently developed and populated with the collected data to calculate total average 
per-patient AE costs associated with the two compared therapy regimens. RESULTS: 
Our analysis shows substantially lower overall per-patient treatment costs for the 
grade 3/4 AE proﬁles observed for both BEV regimens (cisplatin/gemcitabine; carbo-
platin/paclitaxel) than those for the severe AEs observed in the FLEX trial (a1,166 
and a419 versus a2,236). The cost differences favouring BEVCT are mainly attribut-
able to lower incidences of febrile neutropenia, dyspnoea, anaemia, sepsis, and respira-
tory failure. CONCLUSIONS: BEVCT shows better tolerability and lower AE 
treatment costs as compared to CCV. Coupled with its favorable effectiveness, 
BEVCT should be considered as therapy of choice for patients with advanced 
NSCLC.
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OBJECTIVES: Novel combination therapies for advanced NSCLC can offer improved 
survival over chemotherapy alone. However, acceptable tolerability of these new 
therapies is important also in view of the potentially high costs involved in the manage-
ment of severe adverse events (AEs). This analysis explores the AE treatment costs 
related to ﬁrst-line therapy with Bevacizumab (BEV) in combination with chemother-
apy (CT) versus Cetuximab (C) in combination with cisplatin  vinorelbine (CV) in 
patients with advanced NSCLC in Spain. METHODS: All published AEs and their 
incidences as reported in the AVAiL trial (7.5 mg/kg, Reck et al. 2009) and in the         
E4599 trial (15 mg/kg, Sandler et al. 2006) were considered for BEV         CT, whereas 
AE data for the CCV regimen was retrieved from the FLEX trial (Pirker et al. 2009). 
To capture published information on standard treatment patterns and treatment costs 
of AEs, a systematic literature search was performed. Moreover, an oncologist in Spain 
was interviewed to collect additional data on medical resource utilization for the AEs 
under study. These resource use items were then assigned unit costs reﬂective of the 
Spanish health care system. A model was subsequently developed and populated with 
the collected data to calculate total average per-patient AE costs associated with the 
two compared therapy regimens. RESULTS: Treatment costs per patient related to 
grade 3/4 AEs as reported in both BEV NSCLC trials (AVAiL and E4599) are lower 
than those for AEs observed in the FLEX trial (a1192 and a577 vs. a2396). The 
 differences favouring BEVCT are mainly due to lower incidences of neutropenic 
events, leukopenia, sepsis, and respiratory failure when compared to a CCV regimen. 
CONCLUSIONS: BEVCT shows better tolerability and lower AE treatment costs 
as compared to CCV. Coupled with its favorable effectiveness, BEVCT should 
be considered as therapy of choice for patients with advanced NSCLC.
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OBJECTIVES: 90Y Ibritumomab Tiuxetan has been recently approved in the European 
Union as consolidation therapy after remission induction in previously untreated 
patients with B-cell Non-Hodgkin’s Lymphoma (NHL). As a result, the objective of 
the present study was to compare its treatment costs vs. Rituximab maintenance ones 
in Spain. METHODS: A microcosting exercise was performed with Microsoft Excel 
considering Spanish medication and premedication costs for both therapeutic alterna-
tives. Also administration costs were considered. The perspective for cost calculation 
was that of the National Health System. Drug costs were obtained from IMS, posology 
was derived from drug technical speciﬁcations and premedication patterns were 
assessed by expert opinion. Other costs were obtained from specialized sources. Costs 
were expressed in euros 2008. No discounting was needed. The schema of the PRIMA 
study was considered to determine Rituximab maintenance administration pattern. It 
was taken into account that 250 mg/m2 of Rituximab are administered twice, previous 
to 90Y Ibritumomab Tiuxetan consolidation, as premedication. RESULTS: 90Y Ibritu-
momab Tiuxetan consolidation represented a 32% reduction in treatment costs with 
respect to Rituximab maintenance for hospitals in Spain. Absolute ﬁgures accounting 
for medication, premedication, drug preparation and administration costs for both 
therapeutic options were a15,675 for 90Y Ibritumomab Tiuxetan consolidation and 
a22,934 for Rituximab maintenance. If we accounted only for drug costs, absolute 
ﬁgures were: a15,203 for 90Y Ibritumomab Tiuxetan and a21,044 for Rituximab. 
Regarding premedication costs, 16% of 90Y Ibritumomab Tiuxetan consolidation costs 
were due to premedication administered, which is mainly Rituximab and its premedi-
cation, paracetamol and diphenhydramine. CONCLUSIONS: 90Y Ibritumomab 
Tiuxetan consolidation administered once post-chemotherapy in previously untreated 
patients with B-cell NHL is less costly than Rituximab maintenance administered every 
two months for two years in Spain.
